��������

Anna Pryszlak is currently the Director of Antibody Screening at VERAXA Biotech GmbH. Prior to this role, Anna held positions as the Head of Screening and Principal Scientist for Technology Development at Velabs Therapeutics GmbH. Anna has a background in molecular therapy of virus-associated cancers and has experience working as a postdoctoral researcher at EMBL. Anna holds a Doctor of Philosophy degree in Natural Sciences from Heidelberg University.